The features of pregnancy at women with liver steatosis and obesity

Roza Nuraddinovna Rzaeva; Elena Vitalievna Mozgovaya; Ljudmila Konstantinovna Palgova; Valentina Mikchailovna Prokopenko; Zhanna Nikolaevna Tumasova

doi:10.17816/JOWD62647-54

Journal of obstetrics and women's diseases ›› 2013, Vol. 62 ›› Issue (6) : 47 -54. DOI: 10.17816/JOWD62647-54

Articles

research-article

The features of pregnancy at women with liver steatosis and obesity

Author information +

History +

PDF

Abstract

40 pregnant women with obesity were totally examined and their outcomes of pregnancy and delivery were controlled. The examination of all pregnant women included the comprehensive examination of the functional state of the hepatobiliary system, ultrasound examination of the liver to identify the liver steatosis. These medical examinations made possibility to assess the dynamics of a clinical picture, ultrasound conclusions, biochemical indicators of liver function and lipid metabolism during the treatment. The frequency and severity of obstetric complications were also assessed.

Keywords

liver steatosis / obesity / pregnancy / metabolic syndrome / hepatoprotectors

Cite this article

Download citation ▾

Roza Nuraddinovna Rzaeva, Elena Vitalievna Mozgovaya, Ljudmila Konstantinovna Palgova, Valentina Mikchailovna Prokopenko, Zhanna Nikolaevna Tumasova. The features of pregnancy at women with liver steatosis and obesity. Journal of obstetrics and women's diseases, 2013, 62(6): 47-54 DOI:10.17816/JOWD62647-54

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Буеверов А. О. Жирная печень: причины и последствия. Практикующий врач. 2002; 1: 36-38.

[2]	Буеверов А. О. Оксидативный стресс и его роль в повреж дении печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2002; 4: 21-25.

[3]	Буеверов А. О., Богомолов П. О., Маевская М. В., Патогенетическое лечение неалкогольной жировой болезни печени: обоснование, эффективность, безопасность. Терапевтический архив. 2007. С.88-92

[4]	Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени (Методические рекомендации). М., ООО «Издательский дом «М-Вести», 2009

[5]	Голикова Т. П., Дурандин Ю. М., Ермолова Н. П., Кузнецова О. А. Осложнения беременности и родов у женщин с ожирением. Вестник Российской ассоциации акушеров-гинекологов. 1999; 2: 56-58.

[6]	Дедов И. И., Мельниченко Г. А. Ожирение: этиология, патогенез, клинические аспекты. М.: МИА; 2004.

[7]	Комшилова К. А., Дзгоева Ф. Х. Беременность и ожирение. Ожирение и метаболизм. 2009; 4: 9-13.

[8]	Никитин И. Г. Скрининговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания. Российские медицинские вести. 2010; XV (1): 41-6.

[9]	Сметник В. П. Половые гормоны и жировая ткань. Ожирение и метаболизм. 2007; 3 (12): 17-22.

[10]	Соколов Л. К., Минушкин О. Н., Саврасов В. М., Терновой С. К. Клинико-инструментальная диагностика болезней органов гепатопанкреато-дуоденальной зоны. М., 1987.

[11]	Ткач С. М. Распространенность, течение, диагностика и стратегии лечения неалкогольной жировой болезни печени. Здоров’я Украiни. 2009; 1-2 (206-207): 63-5.

[12]	Ребров Б. А., Реброва О. А., Комарова Е. Б. Патология внутренних органов и беременность: учебное пособие. Донецк; 2010.

[13]	Шульпекова Ю. О. Неалкогольная жировая болезнь печени: патогенез, диагностика, лечение. Фарматека. 2007; 6 (141): 48-53.

[14]	Щекина М. И. Неалкогольная жировая болезнь печени. Consilium medicum. 2009; 11 (8): 37-9.

[15]	Alkhouri N., Dixon L., Feldstein A. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert review of gastroenterology hepatology. 2009; 3 (4): 445-51.

[16]	Bellentani S. Immunomodulating and antiapoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur. J. Gastroenterol. Hepatol. 2005; 17: 137-40.

[17]	Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006; 3: 318-28.

[18]	Browning J. D., Horton J. D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004; 114: 147-52.

[19]	Brunt E., Tiniakos D. Pathological features of NASH. Front Biosci. 2005; 10 (4): 1221-31.

[20]	Budianesi E., Vanni E., Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr. Diab. Rep. 2007; 7: 175-80.

[21]	Chang C. Y., Argo C. K., Al-Osaimi A. M., Caldwell S. H. Therapy of NAFLD: antioxidants and cytoprotective agents. J. Clin. Gastroenterol. 2006; 40 (suppl. 1): S51-S60.

[22]	Galtier-Dereure F., Boegner C., Bringer J. Obesity and pregnancy: complications and cost. Am. J. Clin. Nutr. 2000;71 (5 Suppl.): 1242S-8S

[23]	Denison F., Price J. Maternal obesity, lenght of gestation, risk of postdates pregnancy and spontaneous onset of labour at term. BJOG. 2008; 115: 720-5.

[24]	Fan J., Peng Y. Metabolicsyndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat. Dis. Int. 2007; 6 (6): 572-8.

[25]	Fujii H., Ikura Y., Arimoto J. et al. M. Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. J. Atheroscler. Thromb. 2009; 16: 893-901.

[26]	Guelinckx I., Devlieger R. Maternal obesity: pregnancy complications, gestational weight gain and nutrition. J. Complication. 2008; 9: 140-50.

[27]	Hay J. E. Liver disease in pregnancy. Hepatology. 2008; 47 (3): 1067-76.

[28]	Milner K., Van der Poorten D., Xu A. et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology. 2009; 49 (6): 1926-34.

[29]	Misra Vijay Laxmi, Khashab Mouen, Chalasani Naga. Nonalcoholic fatty liver disease and cardiovascular risk. Current Gastroenterology Reports. 2009; 11: 50-5.

[30]	Moseley R. H. Liver and biliary tract. Curr. Opin. Gastroenterol. 2003; 19: 181.

[31]	Muñoz S. J., Martinez-Hernandez A., Maddrey W. C. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology. 1990;12 (2): 342-7.

[32]	Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesisto management: an update. Obesity Reviews. 2010; 11 (6): 430-45.

[33]	Nalpas В., Vassault A., Charpin S. et al. Serum mitochondrial aspartate aminotransferase as a marker of chronic fatty liver disease: diagnostic value and interpretation in a liver unit. Hepatology. 1986; 6: 608-24.

[34]	Nalpas В., Vassault A., Le Guillou A. et al. Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of nonalcoholic fatty liver disease. Hepatology. 1984; 4 (5): 893-6.

[35]	Panther E., Blum H. E. Liver diseases in pregnancy. Dtsch. Med. Wochenschr. 2008; 133 (44): 2283-7.

[36]	Sherlock S., Dooley J. Diseases of liver and biliary system. 10 edn. N.Y; 1997.

[37]	Su G. L. Pregnancy and liver disease. Curr. Gastroenterol. Rep. 2008; 10 (1): 15-21.

[38]	Utzschneider K. M., Kahn S. E. The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metabol. 2006; 91 (12): 4753-61.

[39]	Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R. et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology. 2008; 48: 1791-8.